About one in eight U.S. adults are currently taking a GLP-1 drug such as Ozempic, Wegovy, or Zepbound to treat diabetes, ...

Chennai: People whose immune systems mount an unusually aggressive early response to tuberculosis may be less likely to respond well to standard drug .

The UNESCO Read and Earn Federation (UNESCO REF) and the United Kingdom Global University Application Portal (UAPP) have partnered to provide financial support to Nigerian students seeking higher ...

In a significant labour-market update, Saudi Arabia’s Ministry of Human Resources and Social Development has launched a new digital service that funda.

Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may outperform existing treatments from Apellis Pharmaceuticals and Astellas ...

Carrie Madormo, RN, MPH, is a health writer. She has over a decade of experience as a registered nurse, practicing in a variety of fields, such as pediatrics, oncology, chronic pain, and public health ...

SCRANTON, Pa. — Sergio Chavez Jiminez, a resident and business owner in Danville, was detained by ICE over the weekend. Federals officials tell Newswatch16, Jiminez was detained due an unlawful status ...

After a Danville resident was recently detained by ICE, Newswatch 16's Adi Iyer spoke with a local immigration attorney about the path to citizenship. Analilia Mejia will win New Jersey special ...

Netflix’s latest Korean blockbuster The Great Flood has surged to the top of the platform’s global charts for nonglobal films, but audiences are divided over its cryptic ending and philosophical twist ...

The complement system is an innate immune response that leads to increased inflammation. The drug pegcetacoplan—a complement inhibitor—was approved for medical use in the United States in 2021 to ...

SAN FRANCISCO -- The investigational complement-targeting agent claseprubart was safe and led to significant improvements in generalized myasthenia gravis (MG), the phase II MaGic trial showed. The ...